                                                                                        ®
                                                           Novoeight —  
                                                           Designed to ift  
                                                           into their lives
                                                            A recombinant factor VIII for today’s 
                                                            generation of people living with 
                                                            hemophilia A 1
                                                           Michael, 30 years old, lives with hemophilia A.
        Indications and Usage
        Novoeight® (Antihemophilic Factor [Recombinant]) is indicated for use in adults and children 
        with hemophilia A for control and prevention of bleeding, perioperative management, and 
        routine prophylaxis to prevent or reduce the frequency of bleeding episodes.
        Novoeight® is not indicated for the treatment of von Willebrand disease.
        Important Safety Information
        Do not use in patients who have had life-threatening hypersensitivity reactions, including 
        anaphylaxis, to Novoeight® or its components, including hamster proteins.
        Please see additional Important Safety Information throughout and on page 22. 
        Please see Prescribing Information.
